# Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma

> **NCT05727410** · PHASE2 · RECRUITING · sponsor: **Myung-Ju Ahn** · enrollment: 50 (estimated)

## Conditions studied

- High-grade Salivary Gland Carcinoma

## Interventions

- **DRUG:** nivolumab, docetaxel, cisplatin Group

## Key facts

- **NCT ID:** NCT05727410
- **Lead sponsor:** Myung-Ju Ahn
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-15
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05727410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05727410, "Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05727410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*